TICKERNERD
Menu
DVADVAHealthcare · Medical Care Facilities

DVA Stock Forecast: DaVita, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$234
−2.67% on the day

The 8 Wall Street analysts covering DaVita, Inc. hold a median 12-month price target of $218 — -6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 1 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$15.0B
Ticker Nerd rank
96 / 100
Median analyst target
$218
Analysts covering
8
Total return, dividends reinvested
1W
−1.1%
1M
−0.5%
YTD
+105.7%
1Y
+68.7%
From 52W high
−3.0%
From 52W low
+125.0%
$104
$241
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DaVita, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Revisions
90
Value
86
Quality
85
Volatility
79
Accruals
78
Issuance
66
Growth
56
Size
12

Momentum (90): The shares have been drifting up relative to others.

Growth (56): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own DaVita, Inc. — and when they’d sell — is the membership.

Wall Street

DVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Oct 25Jan 26Apr 26Jul 26DVAHigh $270Median $218Low $145

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
2 Buy4 Hold2 Sell
Low $145Median $218High $270

The green dot is the last close — the median target sits −6.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 July 2026Truist SecuritiesMaintainsHold$205 → $250
10 July 2026UBSMaintainsBuy$235 → $270
9 July 2026BarclaysMaintainsEqual-Weight$194 → $218
11 May 2026TD CowenMaintainsHold—
8 May 2026BarclaysMaintainsEqual-Weight—
8 May 2026Truist SecuritiesMaintainsHold—
7 May 2026UBSMaintainsBuy—
6 May 2026Deutsche BankUpgradeBuy—
4 Feb 2026UBSMaintainsBuy—
3 Feb 2026BarclaysMaintainsEqual-Weight—
3 Nov 2025TD CowenMaintainsHold—
30 Oct 2025BarclaysMaintainsEqual-Weight—
9 Oct 2025BarclaysMaintainsEqual-Weight—
10 Sept 2025B of A SecuritiesMaintainsUnderperform—
7 Aug 2025BarclaysMaintainsEqual-Weight—
19 May 2025Truist SecuritiesMaintainsHold—
18 Feb 2025BarclaysMaintainsEqual-Weight—
31 Oct 2024BarclaysMaintainsEqual-Weight—
7 Oct 2024Truist SecuritiesMaintainsHold—
20 Aug 2024Truist SecuritiesMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.0%
Analysts raising
7
Analysts cutting
0
Fundamentals

DaVita, Inc. (DVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.5×

Cheaper than 35% of US stocks

Price / sales
1.1×

Cheaper than 68% of US stocks

Price / book
15.0×

Cheaper than 7% of US stocks

EV / EBITDA
10.7×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
6.0%

Higher than 44% of US stocks

Earnings growth (YoY)
21.2%

Higher than 62% of US stocks

Gross margin
31.4%

Higher than 38% of US stocks

Operating margin
13.9%

Higher than 72% of US stocks

Net margin
5.6%

Higher than 61% of US stocks

Returns & dividend
Return on equity
81.0%

Higher than 95% of US stocks

Return on assets
7.5%

Higher than 87% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
DVADaVita, Inc.$15.0B
96
THCTenet Healthcare Corp.$20.5B
96
EHCEncompass Health Corp.$11.0B
75
UHSUniversal Health Services, Inc.$10.5B
64
ENSGThe Ensign Group, Inc.$10.3B
69
PACSPACS Group, Inc.$7.1B
91
CHEChemed Corp.$7.1B
88
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DVA news & analysis

Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?

Zacks Investment Research · 3 Aug 2026neutral

A Zacks Research report discusses the outlook for DaVita's (DVA) forthcoming Q2 results, noting that volume growth and recovery in reimbursement per treatment (RPT) are likely to support results, while payor mix pressure and technology spending could limit margin gains.

Why it matters — The report flags the key offsetting drivers that could shape DaVita's near-term quarterly performance, giving DVA watchers a sense of the risks and supports ahead of Q2 results.

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

Zacks Investment Research · 29 July 2026neutral

Zacks Investment Research noted that DaVita's stock is supported by its IKC momentum, higher 2026 guidance, and technology investments, while also facing reimbursement and payer-mix risks.

Why it matters — A DVA watcher would care because the piece highlights both the growth drivers and the risks that could affect the company's financial performance and stock outlook.

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

Zacks Investment Research · 28 July 2026positive

DaVita HealthCare (DVA) shares closed at $239.46, up 1.33% from the previous trading day, outperforming the broader stock market.

Why it matters — The stock's positive price movement indicates it gained ground relative to the overall market in the latest trading session.

FAQ

Frequently asked questions about DVA stock

What is the DVA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering DaVita, Inc. have a median 12-month price target of $218, with estimates ranging from $145 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DVA stock a buy right now?

Of the 8 analysts covering DaVita, Inc., 2 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks DaVita, Inc. 96 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DVA?

As at 1 Aug 2026, DaVita, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will DVA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies -6.7% from the last close, and Ticker Nerd's factor model ranks DaVita, Inc. 96 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DVA stock forecast for 2030?

No analyst covering DaVita, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $270 over the next 12 months.

How has DVA stock performed over the past year?

DaVita, Inc. returned +68.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DaVita, Inc. do?

DaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease.

What is the latest news on DVA?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?". A Zacks Research report discusses the outlook for DaVita's (DVA) forthcoming Q2 results, noting that volume growth and recovery in reimbursement per treatment (RPT) are likely to support results, while payor mix pressure and technology spending could limit margin gains.

Company

About DaVita, Inc.

DaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease. The company operates a large network of outpatient dialysis centers, where it delivers in-center hemodialysis and related care services to adult patients across the United States and internationally. DaVita Inc. also supports home-based dialysis modalities, offering peritoneal dialysis and home hemodialysis, along with clinical education and support programs to help patients manage treatment outside the clinic setting. In addition, the company operates clinical laboratories that perform routine and specialized tests for dialysis patients and provides management and administrative services to affiliated outpatient centers. Headquartered in Denver, Colorado, DaVita Inc. plays a significant role in the healthcare system by serving a critical, medically complex patient population and working alongside physicians, hospitals, and payers to coordinate kidney care and related services.

CEO Mr. Javier J. Rodriguez · 78,000 employees · United States · https://www.davita.com